1.9(top 50%)
2-year impact
2.1(top 20%)
3-year impact
1.9(top 50%)
5-year impact
2.1(top 20%)
10-year impact
705(top 20%)
PR articles
6.3K(top 20%)
PR citations
29(top 20%)
PR h-index
57(top 10%)
h-index
2.0(top 50%)
extended IF
5.1(top 5%)
2-YI (article-only)
3.7(top 50%)
2-YI (review-only)
0.1(top 100%)
2-YI (comm only)
1.9(top 20%)
2-YI (no self-cite.)
1.8K
documents
25.8K
doc citations

Top Articles

#TitleJournalYearCitations
1OncoKB: A Precision Oncology Knowledge BaseJCO Precision Oncology20171,457
2Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid LeukemiaJCO Precision Oncology2019349
3Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain EfficacyJCO Precision Oncology2018274
4Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to EntrectinibJCO Precision Oncology2017263
5Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene FusionJCO Precision Oncology201792
6Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung CancersJCO Precision Oncology201990
7Rationale and Design of the Targeted Agent and Profiling Utilization Registry StudyJCO Precision Oncology201888
8Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive ReviewJCO Precision Oncology202086
9Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung CancersJCO Precision Oncology201873
10METExon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing ConsiderationsJCO Precision Oncology202168
11Homologous Recombination Deficiency in Breast Cancer: A Clinical ReviewJCO Precision Oncology201762
12Clinical Outcomes of Molecular Tumor Boards: A Systematic ReviewJCO Precision Oncology202161
13Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast CancerJCO Precision Oncology202260
14Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung CancerJCO Precision Oncology202256
15Precision Oncology and the Universal Health Coverage System in JapanJCO Precision Oncology201953
16Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical ConsiderationsJCO Precision Oncology201953
17Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsJCO Precision Oncology201952
18Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature ReviewJCO Precision Oncology202148
19Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsJCO Precision Oncology202247
20PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJCO Precision Oncology202246
21Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer CareJCO Precision Oncology202242
22Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 BlockadeJCO Precision Oncology201841
23Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung CancerJCO Precision Oncology201941
24Drug-Related Pneumonitis in the Era of Precision Cancer TherapyJCO Precision Oncology201740
25Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer PreventionJCO Precision Oncology202139
26Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced CancerJCO Precision Oncology202339
27Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets SuperiorityJCO Precision Oncology201937
28Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer CareJCO Precision Oncology202436
29First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic LeukemiaJCO Precision Oncology201834
30Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic CancerJCO Precision Oncology201833
31Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future ChallengesJCO Precision Oncology202233
32Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsJCO Precision Oncology201832
33Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to AlpelisibJCO Precision Oncology202032
34Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1JCO Precision Oncology202032
35Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast CarcinomaJCO Precision Oncology201730
36ALK Fusions in Renal Cell Carcinoma: Response to EntrectinibJCO Precision Oncology201829
37Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal MetastasesJCO Precision Oncology201929
38Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern OncologyJCO Precision Oncology201929
39Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene AlterationsJCO Precision Oncology202029
40Complete and Prolonged Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal CancerJCO Precision Oncology201928
41Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology PracticeJCO Precision Oncology202128
42Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair GenesJCO Precision Oncology202228
43Economic Evaluations of Next-Generation Precision Oncology: A Critical ReviewJCO Precision Oncology201827
44Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic LeukemiaJCO Precision Oncology201927
45Next-Generation Sequencing and the Clinical Oncology Workflow: Data Challenges, Proposed Solutions, and a Call to ActionJCO Precision Oncology201926
46Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)JCO Precision Oncology202126
47STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib TreatmentJCO Precision Oncology201925
48Implications of Clonal Hematopoiesis for Precision OncologyJCO Precision Oncology202024
49Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision OncologyJCO Precision Oncology202124
50A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate CancerJCO Precision Oncology202023